Research Reports

While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: “in-stent thrombosis”. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.

In the 21st Century there is a growing trend towards the development of personalized medicine – the right drug for the right individual. Examine the rapidly advancing fields of pharmacogenomics and pharmacogenetics, and measure the impact of pharmacogenomic techniques on reimbursement and health economics with this new report.

The Cardiovascular Disorders Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the period 2007-12.

An overview of the challenges facing the life science industry in 2008 Datamonitor's take on the technology priorities of pharmaceutical and biotechnology companies Strategies to help technology vendors penetrate the life science industry.

Use this report to develop effective pricing strategies based upon this report’s unique market forecasts for future pricing scenarios in key markets and understand the major issues affecting the global pricing landscape.

Declining growth rates in developed markets mean many pharmaceutical companies are turning their attention to developing markets.

Use this report to gain an understanding of the major drivers and resistors to generic growth in each of the 7 major markets.

Electronic health records (EHRs) will be the cornerstone of healthcare technology. The design, selection and implementation of EHRs, therefore, will be extremely important for healthcare institutions.

This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market.

The medical establishment's approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patient's, but rather is shared among stakeholders. Learn how communication between patients, physicians and the pharmaceutical industry impacts rates of adherence.